These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24852755)

  • 21. 3-Deazaneplanocin A (DZNep), an inhibitor of S-adenosylmethionine-dependent methyltransferase, promotes erythroid differentiation.
    Fujiwara T; Saitoh H; Inoue A; Kobayashi M; Okitsu Y; Katsuoka Y; Fukuhara N; Onishi Y; Ishizawa K; Ichinohasama R; Harigae H
    J Biol Chem; 2014 Mar; 289(12):8121-34. PubMed ID: 24492606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 3-deazaneplanocin A, a histone methyltransferase inhibitor, improved the chemoresistance induced under hypoxia in melanoma cells.
    Hosokawa M; Tetsumoto S; Yasui M; Kono Y; Ogawara KI
    Biochem Biophys Res Commun; 2023 Oct; 677():26-30. PubMed ID: 37542772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-Treatment with the Epigenetic Drug, 3-Deazaneplanocin A (DZNep) and Cisplatin after DZNep Priming Enhances the Response to Platinum-Based Therapy in Chondrosarcomas.
    Lhuissier E; Aury-Landas J; Lenté M; Boumediene K; Baugé C
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells.
    Benoit YD; Laursen KB; Witherspoon MS; Lipkin SM; Gudas LJ
    J Cell Physiol; 2013 Apr; 228(4):764-72. PubMed ID: 23001792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.
    Miranda TB; Cortez CC; Yoo CB; Liang G; Abe M; Kelly TK; Marquez VE; Jones PA
    Mol Cancer Ther; 2009 Jun; 8(6):1579-88. PubMed ID: 19509260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
    Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC
    Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DZNep promotes mouse bone defect healing via enhancing both osteogenesis and osteoclastogenesis.
    Cao X; He W; Rong K; Xu S; Chen Z; Liang Y; Han S; Zhou Y; Yang X; Ma H; Qin A; Zhao J
    Stem Cell Res Ther; 2021 Dec; 12(1):605. PubMed ID: 34930462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis.
    Jiang Y; Xiang C; Zhong F; Zhang Y; Wang L; Zhao Y; Wang J; Ding C; Jin L; He F; Wang H
    Theranostics; 2021; 11(1):361-378. PubMed ID: 33391480
    [No Abstract]   [Full Text] [Related]  

  • 29. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway.
    Zhang P; Yang X; Ma X; Ingram DR; Lazar AJ; Torres KE; Pollock RE
    Mol Cancer; 2015 Mar; 14():55. PubMed ID: 25890085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
    Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
    Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological reversal of histone methylation presensitizes pancreatic cancer cells to nucleoside drugs: in vitro optimization and novel nanoparticle delivery studies.
    Hung SW; Mody H; Marrache S; Bhutia YD; Davis F; Cho JH; Zastre J; Dhar S; Chu CK; Govindarajan R
    PLoS One; 2013; 8(8):e71196. PubMed ID: 23940717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
    Hayden A; Johnson PW; Packham G; Crabb SJ
    Breast Cancer Res Treat; 2011 May; 127(1):109-19. PubMed ID: 20556507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EZH2-inhibitor DZNep enhances apoptosis of renal tubular epithelial cells in presence and absence of cisplatin.
    Chen SQ; Li JQ; Wang XQ; Lei WJ; Li H; Wan J; Hu Z; Zou YW; Wu XY; Niu HX
    Cell Div; 2020; 15():8. PubMed ID: 32508971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
    Cui B; Yang Q; Guan H; Shi B; Hou P; Ji M
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E962-70. PubMed ID: 24512488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.
    Bate-Eya LT; Gierman HJ; Ebus ME; Koster J; Caron HN; Versteeg R; Dolman MEM; Molenaar JJ
    Eur J Cancer; 2017 Apr; 75():63-72. PubMed ID: 28214660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deazaneplanocin a is a promising drug to kill multiple myeloma cells in their niche.
    Gaudichon J; Milano F; Cahu J; DaCosta L; Martens AC; Renoir JM; Sola B
    PLoS One; 2014; 9(9):e107009. PubMed ID: 25255316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
    Kemp CD; Rao M; Xi S; Inchauste S; Mani H; Fetsch P; Filie A; Zhang M; Hong JA; Walker RL; Zhu YJ; Ripley RT; Mathur A; Liu F; Yang M; Meltzer PA; Marquez VE; De Rienzo A; Bueno R; Schrump DS
    Clin Cancer Res; 2012 Jan; 18(1):77-90. PubMed ID: 22028491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.
    Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J
    BJU Int; 2016 Feb; 117(2):351-62. PubMed ID: 24612432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting enhancer of zeste homolog 2 protects against acute kidney injury.
    Zhou X; Zang X; Guan Y; Tolbert T; Zhao TC; Bayliss G; Zhuang S
    Cell Death Dis; 2018 Oct; 9(11):1067. PubMed ID: 30341286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.